Literature DB >> 15607899

The paraoxonase gene family and atherosclerosis.

Carey J Ng1, Diana M Shih, Susan Y Hama, Natividad Villa, Mohamad Navab, Srinivasa T Reddy.   

Abstract

Epidemiologic, genetic, and biochemical studies support an antiatherogenic role for paraoxonase (PON) 1. While the precise mechanism by which PON1 protects against the development of atherosclerosis is unclear, in vitro studies and the results from PON1 knockout and transgenic mice suggest that this protective effect may be attributed to PON1's ability to attenuate the oxidative modification of lipoprotein particles. The two other members of the PON gene family, namely, PON2 and PON3, have also been reported to possess antioxidant properties and may exhibit antiatherogenic capacities as well. Previous studies have demonstrated that PON1 expression is downregulated by oxidative stress. In contrast, more recent studies have shown that PON2 expression is upregulated in response to oxidative stress-inducing agents, while PON3 expression remains unchanged. While the physiological function of these proteins is unknown, studies currently underway using PON2 and PON3 knockout and transgenic mice should enable us to tease out the apparently redundant functions of these three proteins and yield clues as to their physiological function as well as their role in atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15607899     DOI: 10.1016/j.freeradbiomed.2004.09.035

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  70 in total

Review 1.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

2.  Paraoxonase 1, 2 and 3 DNA variants and susceptibility to childhood inflammatory bowel disease.

Authors:  R Sanchez; E Levy; E Seidman; D Amre; F Costea; D Sinnett
Journal:  Gut       Date:  2006-12       Impact factor: 23.059

Review 3.  Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on.

Authors:  Lucio G Costa; Gennaro Giordano; Clement E Furlong
Journal:  Biochem Pharmacol       Date:  2010-11-18       Impact factor: 5.858

Review 4.  Quorum-quenching microbial infections: mechanisms and implications.

Authors:  Y-h Dong; L-y Wang; L-H Zhang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-07-29       Impact factor: 6.237

Review 5.  The roles of PON1 and PON2 in cardiovascular disease and innate immunity.

Authors:  Diana M Shih; Aldons J Lusis
Journal:  Curr Opin Lipidol       Date:  2009-08       Impact factor: 4.776

6.  Paraoxonase 3 functions as a chaperone to decrease functional expression of the epithelial sodium channel.

Authors:  Shujie Shi; Nicolas Montalbetti; Xueqi Wang; Brittney M Rush; Allison L Marciszyn; Catherine J Baty; Roderick J Tan; Marcelo D Carattino; Thomas R Kleyman
Journal:  J Biol Chem       Date:  2020-02-20       Impact factor: 5.157

7.  No influence of increased intake of orange and blackcurrant juices and dietary amounts of vitamin E on paraoxonase-1 activity in patients with peripheral arterial disease.

Authors:  Christine Dalgård; Lene Christiansen; Torbjörn Jonung; Michael I Mackness; Moniek P M de Maat; Mogens Hørder
Journal:  Eur J Nutr       Date:  2007-08-21       Impact factor: 5.614

8.  Role of paraoxonase-1 in the protection of hydrogen sulfide-donating sildenafil (ACS6) against homocysteine-induced neurotoxicity.

Authors:  Xiao-Qing Tang; Rong-Qian Chen; Ling Dong; Yan-Kai Ren; Piero Del Soldato; Anna Sparatore; Duan-Fang Liao
Journal:  J Mol Neurosci       Date:  2012-07-29       Impact factor: 3.444

9.  A high throughput serum paraoxonase assay for discovery of small molecule modulators of PON1 activity.

Authors:  Tiffany L Graves; John E Scott
Journal:  Curr Chem Genomics       Date:  2008-11-26

10.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Authors:  Leonid Gaidukov; Dganit Bar; Shiri Yacobson; Esmira Naftali; Olga Kaufman; Rinat Tabakman; Dan S Tawfik; Etgar Levy-Nissenbaum
Journal:  BMC Clin Pharmacol       Date:  2009-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.